FDA Clocks Review Time, Boosts NIKTIMVO Patent Lifeline
Published Date: 9/29/2025
Notice
Summary
The FDA has officially set the review period for NIKTIMVO, a human biological product, so its patent can be extended. This helps the company behind NIKTIMVO get extra time to protect their invention. If you’re involved in patents or drug development, this timing update matters for planning and legal steps.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
FDA Sets Review Period for NIKTIMVO
The FDA has determined the regulatory review period for NIKTIMVO, a human biological product, which enables the patent holder to pursue a patent-term extension with the U.S. Patent and Trademark Office. If you work in patents or drug development, this timing update matters for planning and legal steps related to extending patent protection.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in